USTR Proposes Extra Intellectual Property Protection for Biologic Drugs in the Trans Pacific Partnership (TPP)

At last week’s round of Trans Pacific Partnership (TPP) negotiations in Salt Lake City, access to medicines campaigners reported that the U.S. administration tabled a new proposal aimed at protecting brand name biologic drug companies from generic competition through a twelve year period of data exclusivity (a form of protection separate and in addition to [...]